RxDoctor Payments Data

Suzanne McAdams, MD

Neurology · Boone, NCNPI 1497854889

Payments from drug & device makers

$6,048in general payments, 2019–2025

Across 372 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$618
  • Amneal Pharmaceuticals LLC$532
  • Sunovion Pharmaceuticals Inc.$500
  • EMD Serono, Inc.$345
  • UCB, Inc.$290
  • Harmony Biosciences LLC$274
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,018100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,048 in reported general payments places this provider in the 65th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$198,462
Medicare patients
467
Services billed
2,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4680$502,302
XywavSodium,calcium,mag,pot Oxybate18$295,410
Sodium Oxybate15$227,465
IngrezzaValbenazine Tosylate12$103,314
Kesimpta PenOfatumumab12$101,892
FingolimodFingolimod Hcl12$86,614
CopaxoneGlatiramer Acetate14$80,015
NuplazidPimavanserin Tartrate16$79,917
NuedextaDextromethorphan Hbr/Quinidine47$77,415
Aimovig AutoinjectorErenumab-Aooe89$66,722
FycompaPerampanel44$59,465
EpidiolexCannabidiol (Cbd)15$46,977
UbrelvyUbrogepant32$42,175
Nurtec OdtRimegepant Sulfate36$38,602
QuliptaAtogepant31$37,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$53$502,30280 claims
Eisai Inc.Fycompa, Banzel$99$83,92755 claims
AbbVieUbrelvy, Qulipta$156$80,10263 claims
Teva Pharmaceuticals USA, Inc.Copaxone$207$80,01514 claims
Acadia Pharmaceuticals IncNuplazid$259$79,91716 claims
PfizerNurtec Odt$32$38,60236 claims
MDD US Operations, LLCGocovri$201$35,79211 claims
UCB, Inc.Vimpat$290$29,32223 claims
SK Life Science, Inc.Xcopri$55$23,51021 claims
Amneal Pharmaceuticals LLCRytary$532$18,77716 claims
Lundbeck LLCOnfi$53$17,39813 claims
Sunovion Pharmaceuticals Inc.Aptiom$500$14,62012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 566 neurology providers in North Carolina.

Other neurology in Boone

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →